Lilly's Inluriyo Shows Positive Results in Advanced Breast Cancer Trial
AI Summary1 min read
TL;DR
Eli Lilly's Inluriyo (imlunestrant) demonstrated positive Phase 3 results in advanced breast cancer, reducing progression/death risk by 38% as monotherapy and 41% in combination with abemaciclib, with consistent safety.
Tags
Eli Lilly
Eli Lilly's Inluriyo (imlunestrant) has shown positive results in a Phase 3 trial for advanced breast cancer. As monotherapy, it reduced the risk of progression or death by 38% and improved median overall survival by 11.4 months in patients with ESR1-mutated disease. The combination of imlunestrant and abemaciclib reduced the risk of progression or death by 41% and showed a favorable overall survival trend. Safety profiles remained consistent with earlier reports.
